About us

Home >

Biofordrug was founded in 2011 by four academics from the University of Bari, Nicola A. Colabufo, Marcello Leopoldo, Roberto Perrone and Francesco Berardi.

Biofordrug’s key missions are:

– discovery of fluorescent probes and PET radiotracers for early diagnosis of neurodegenerative and tumor diseases;

– discovery of innovative, proprietary drugs for neurodevelopmental diseases (i.e. Fragile-X syndrome, Rett syndrome).

Biofordrug’s activities also include:

– development of in-vitro diagnostic kits for neurodegenerative and tumor pathologies

– analysis and certification of stability of drugs in elastomeric infusors for third parties

– screening and profiling of drug candidates for biotech companies

Biofordrug has developed an in-vitro serum copper assay for early diagnosis of Alzheimer’s disease in partnership with Agostino Gemelli University Polyclinic (Rome, Italy), Fatebenefratelli Hospital (Rome, Italy) and Campus Bio-medico (Rome, Italy). The know-how was transferred to Canox4Drug company (www.canox4drug.com). Biofordrug currently owns 20% shares of Canox4Drug. The test has been approved by the Italian Ministry of Health.

Biofordrug is partner in the project “PET radiotracers development useful for neurodegenerative and oncological disease early diagnosis” funded by STW Nederland (Dutch agency for applied university research) (2011-2015). The developed18F-radiotracers are in clinical trials at the Nuclear Medicine Institutes of Groningen and Amsterdam in partnership with IBA, Cyclotron and Bayer.

Biofordrug is partner in the project “Development of nanotechnological dispensing-systems of antitumour drugs to overcome drug resistance” funded by the Italian Ministry of Education, Universities and Research within the framework of Programma Operativo Nazionale PON (PACO2L3_00087) REC-startup (Social Innovation Cluster) (2013-2015).

Biofordrug is member of the network “D3i4AD – Diagnostic and Drug Discovery Initiative for Alzheimer’s Disease” funded by European Union within the Framework Program 7, Marie Curie Industry-Academia Partnerships and Pathways (IAPP) (2013-2015).

Biofordrug is partner in the project “Innovative drugs for treatment of cognitive deficits in neurodegenerative diseases and age-related disorders” funded by the Italian Ministry of Foreign Affairs within the framework of the executive programme for scientific and technological cooperation between Italy and Poland (2013-2015).

Biofordrug is partner in the project “Development of nanotechnological dispensing-systems of antitumour drugs to overcome drug resistance” funded by the Italian Ministry of Education, Universities and Research within the framework of Programma Operativo Nazionale PON (PACO2L3_00087) REC-startup (Social Innovation Cluster) (2013-2015).

Biofordrug is Certified UNI EN ISO 9001-2008 N° 10566-A

– Biomolecular research in neurological and oncological fields.

– Clinical biology, toxicology, molecular biology and nutraceutical

Biofordrug is affiliated to Confindustria, the main association representing manufacturing and service companies in Italy.

>>Download Arab version

Quality Management System Certificate